Halloween probably feels like an ominous time for a sponsor with an important new drug application to go before a US FDA advisory committee. At the very least, it is an inconvenient date for any parents of Trick-or-Treat-age children.
But for Indivior PLC and Braeburn Pharmaceuticals Inc., it is hard to imagine a better-timed advisory committee meeting...





